Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 105

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 105
---

confidentiality agreements with parties who have access to them, such as our employees, consultants, advisors and other third parties.
We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts,
any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized
uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual
property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that
a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.
In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.

<div align='center'>53</div>

Moreover, our competitors
may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and
replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent
protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right
to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade
secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we will rely on
third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect
our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting
agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research
or disclosing proprietary information. These agreements typically limit the rights of the third parties to use and disclose our confidential
information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share
trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently
incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position